Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 26

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 26
---
     |         |         |     |                                                 |  2,940 |     |                            |     8,158 |     |                                              |         — |     |             |     |     |        |         — |
| Share-based compensation                   |     |                                              |         |     |         |         |     |                                                 |        |     |                            |         — |     |                                              |    54,997 |     |             |     |     |        |    54,997 |
| Exercise of share-based awards             |     |                                              |         |     |         |         |     |                                                 |        |     |                            |         — |     |                                              |   -36,129 |     |             |     |     |        |   -36,129 |
| Total transactions with owners             |     |                                              |       — |     |         |       — |     |                                                 |  2,940 |     |                            |     8,158 |     |                                              |  -250,106 |     |             |   — |     |        |  -250,106 |
| As of December 31, 2024                    |     |                                              | -58,854 |     |         |  -6,783 |     |                                                 |      — |     |                            | 2,701,502 |     |                                              | 7,418,274 |     |             | 917 |     |        | 7,419,191 |

<div align='center'>20</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

(5) Condensed Interim Consolidated Statements of Cash Flows

|                                                                                                                     |     | JPY (millions)                       
 Nine-month Period Ended December 31, |     2023 |     |     |     2024 |
|:--------------------------------------------------------------------------------------------------------------------|:----|:-------------------------------------|---------:|:----|:----|---------:|
| Cash flows from operating activities:                                                                               |     |                                      |          |     |     |          |
| Net profit for the period                                                                                           |     |                                      |  147,191 |     |     |  211,241 |
| Depreciation and amortization                                                                                       |     |                                      |  541,258 |     |     |  571,627